Dopamine, a key neurotransmitter in the brain, plays a vital role in regulating movement, emotion, and cognition. It is central to the pathology of several major neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, and bipolar disorder. These conditions, though distinct in their symptoms and progression, share a common feature: the disruption of dopamine signalling pathways. Understanding how dopamine dysfunction contributes to these disorders provides insight into their underlying mechanisms and guides the development of effective treatments.

Parkinson's disease: Dopamine deficiency and motor dysfunction

Parkinson's disease (PD) is a degenerative neurological disorder that affects movement, leading to symptoms like tremors, bradykinesia (slowness of movement), rigidity, and postural instability. PD is caused by the loss of dopamine-producing neurons in the substantia nigra, a part of the brain that plays a critical role in motor control. By the time symptoms appear, a significant number of these neurons have already been lost, making early detection a challenge.

Dopamine is essential for smooth, coordinated movement. In PD, the decline in dopamine levels disrupts this coordination, leading to the hallmark motor symptoms. Research has shown that early in the disease, there is an increase in D2 receptors in the striatum (a key area involved in motor function), but this effect reverses over time, contributing to the progression of motor impairment.

The exact cause of PD remains unclear, though genetic factors play a role in 5-10% of cases. Environmental factors, such as exposure to pesticides and rural living, also contribute to the risk, with age being the most significant factor. The prevalence of PD is between 8 to 18 per 100,000 people annually in industrialized countries, and men are more likely to develop the disease.

Treatment for Parkinson's centres on dopamine replacement, with levodopa being the gold standard. Levodopa crosses the blood-brain barrier and is converted into dopamine in the brain, helping alleviate symptoms. However, levodopa has limitations, including side effects such as nausea, hallucinations, and impulse control disorders, as well as the eventual development of motor fluctuations and dyskinesia (involuntary movements). To mitigate these side effects, levodopa is often combined with a decarboxylase inhibitor or extended-release formulations.

Dopamine agonists, which directly stimulate dopamine receptors, are another treatment option. These drugs are less effective than levodopa but carry a lower risk of dyskinesia. However, they also present side effects, including leg oedema, increased daytime sleepiness, and a higher risk of impulse control disorders. Other medications, such as monoamine oxidase B inhibitors, help prolong the effects of dopamine by reducing its breakdown.

For patients with advanced PD, deep brain stimulation (DBS) is a viable option. DBS involves the implantation of electrodes in the brain to deliver electrical impulses to specific areas, such as the subthalamic nucleus or globus pallidus, to alleviate motor symptoms. DBS has been shown to significantly improve the quality of life for patients with advanced PD, often outperforming pharmacological treatments in controlling motor symptoms.

Schizophrenia: Dopamine dysregulation and psychosis

Schizophrenia is a complex psychiatric disorder characterized by a combination of positive symptoms (such as hallucinations and delusions) and negative symptoms (such as social withdrawal and emotional blunting). Affecting about 1% of the population, schizophrenia typically emerges in young adulthood, with men showing a slightly higher prevalence.

The "dopamine hypothesis" of schizophrenia has been a dominant theory in understanding the disorder's neurochemical basis. This hypothesis suggests that hyperactivity in dopamine pathways, particularly in the midbrain, contributes to the positive symptoms of schizophrenia. Antipsychotic medications, the mainstay of schizophrenia treatment, work by blocking dopamine D2 receptors, thus reducing the excessive dopamine activity associated with psychotic episodes.

Studies in individuals with schizophrenia have shown abnormal dopamine signalling, particularly an over activity in the mesolimbic pathway, which is linked to reward and emotion. This over activity is believed to drive the hallucinations and delusions characteristic of the disorder. At the same time, dopamine hypofunction in other brain regions may underlie the negative symptoms, such as reduced motivation and blunted affect.

The treatment of schizophrenia has evolved over time, with antipsychotic medications classified into typical (first-generation) and atypical (second-generation) drugs. Typical antipsychotics primarily target D2 receptors and are effective in controlling positive symptoms, but they come with significant side effects, including parkinsonism and tardive dyskinesia (involuntary facial movements). Atypical antipsychotics, while still targeting dopamine receptors, also act on other neurotransmitter systems and tend to have a better side effect profile, though they are associated with weight gain and metabolic disturbances.

In addition to medication, psychosocial interventions such as cognitive behavioral therapy (CBT), family therapy, and supported employment programs play a crucial role in managing schizophrenia. CBT, in particular, helps individuals cope with delusions and hallucinations by addressing dysfunctional thought patterns. While medication remains the cornerstone of treatment, these interventions can significantly improve a patient's overall quality of life.

Bipolar disorder: Dopamine and mood dysregulation

Bipolar disorder (BD) is a mood disorder characterized by episodes of mania and depression. It encompasses several subtypes, including bipolar I (characterized by full manic episodes) and bipolar II (characterized by hypomanic episodes and severe depression). BD affects about 1-2% of the population and is associated with significant psychosocial impairment and increased risk of suicide.

Dopamine dysregulation plays a crucial role in the pathophysiology of BD, particularly during manic episodes. During mania, heightened dopamine activity in brain regions such as the mesolimbic pathway (involved in reward processing) is observed. This increase in dopamine is thought to contribute to the elevated mood, increased energy, and impulsivity seen in mania. Conversely, reduced dopamine function may be associated with depressive episodes in BD.

The genetic component of BD is strong, with heritability estimates as high as 85%. Studies have shown that BD shares genetic links with both schizophrenia and major depressive disorder, highlighting the complex nature of its aetiology. However, despite advances in understanding the genetic and neurochemical underpinnings of BD, its precise cause remains elusive.

The treatment of bipolar disorder involves a combination of pharmacotherapy, psychosocial interventions, and lifestyle modifications. For acute mania, antipsychotics, lithium, and mood stabilizers such as divalproex and carbamazepine are commonly used. Lithium, in particular, remains the gold standard for long-term mood stabilization and has been shown to reduce the risk of suicide in patients with BD. However, it requires regular monitoring due to its narrow therapeutic range and potential side effects, such as kidney and thyroid dysfunction.

In treating bipolar depression, options such as quetiapine, cariprazine, and the combination of olanzapine and fluoxetine are available. However, these medications can lead to weight gain, metabolic disturbances, and other long-term side effects, emphasizing the need for careful management.

Psychosocial interventions, including CBT, peer support, and psychoeducation, are crucial components of BD management. These therapies not only help patients cope with the emotional and cognitive challenges of BD but also improve treatment adherence and reduce the risk of relapse. For patients with treatment-resistant BD, neurostimulation techniques such as repetitive transcranial magnetic stimulation (rTMS) are being explored as alternatives to more invasive procedures like electroconvulsive therapy (ECT).

Conclusion

Dopamine plays a central role in the functioning of the brain, and its dysregulation is implicated in a wide range of neurological and psychiatric disorders. Parkinson's disease, schizophrenia, and bipolar disorder, though distinct in their presentations, are all linked by disruptions in dopamine signalling. Understanding these disruptions has been key to developing treatments that alleviate symptoms and improve the quality of life for affected individuals.

While current treatments offer significant benefits, they also come with limitations, such as side effects and the potential for long-term complications. As research into the mechanisms of dopamine dysregulation continues, there is hope for more targeted and effective therapies that address the root causes of these disorders rather than just their symptoms. With advancements in pharmacotherapy, neurostimulation, and psychosocial interventions, the future holds promise for improving outcomes for individuals living with these challenging conditions.

Renald Blundell is a biochemist and biotechnologist with a special interest in Natural and Alternative Medicine. He is a professor at the Faculty of Medicine and Surgery, University of Malta.

Lara Arslan is currently a medical student at the University of Malta.

Photo: AI-generated image created by Prof. Blundell